FuelCell Energy progress in two SOFC projects with DOE

Risedronate decreases biochemical marker

Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study

✍ Clifton O. Bingham III; J. Chris Buckland-Wright; Patrick Garnero; Stanley B. Co 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB 👁 2 views

## Abstract ## Objective Bisphosphonates have slowed the progression of osteoarthritis (OA) in animal models and have decreased pain in states of high bone turnover. The Knee OA Structural Arthritis (KOSTAR) study, which is the largest study to date investigating a potential structure‐modifying OA